Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929245 | 0.93 | GRM5 (0.44) | GRM5ALDH1A1GAAMAPTTDP1 | |
| SCHEMBL929935 | 0.90 | GRM5 (0.42) | GRM5CYP11B1CYP11B2ALDH1A1GAA | |
| SCHEMBL928584 | 0.89 | GRM5 (0.52) | GRM5ALDH1A1GAAMAPTTDP1 | |
| SCHEMBL927729 | 0.88 | GRM5 (0.49) | GRM5ALDH1A1GAAMAPTTDP1 | |
| SCHEMBL930122 | 0.88 | GRM5 (0.48) | GRM5ALDH1A1GAAMAPTTDP1 | |
| SCHEMBL3816597 | 0.86 | WDR5 (0.35) | CYP11B1CYP11B2WDR5 | |
| SCHEMBL929205 | 0.86 | GRM5 (0.47) | GRM5ALDH1A1GAAMAPTTDP1 | |
| SCHEMBL930066 | 0.86 | GRM5 (0.49) | GRM5ALDH1A1GAAMAPTTDP1 | |
| SCHEMBL930065 | 0.85 | GRM5 (0.48) | GRM5ALDH1A1GAAMAPTTDP1 | |
| SCHEMBL929417 | 0.85 | GRM5 (0.46) | GRM5ALDH1A1GAAMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20110003820-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-01-06 | — | — | US | disclosed |
| EP-2247590-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009095254-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | disclosed |
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003820-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | GRM5, GRIK5, GRK5 | GRM5 1/4885CYP11B1 1162/4885CYP11B2 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.